BidaskClub upgraded shares of Phibro Animal Health (NASDAQ:PAHC) from a strong sell rating to a sell rating in a report issued on Tuesday morning.
PAHC has been the subject of several other research reports. Zacks Investment Research downgraded shares of Phibro Animal Health from a hold rating to a sell rating in a research note on Wednesday, August 29th. Morgan Stanley lifted their price target on shares of Phibro Animal Health from $36.00 to $46.00 and gave the company an underweight rating in a research note on Wednesday, August 29th. Finally, ValuEngine downgraded shares of Phibro Animal Health from a buy rating to a hold rating in a research note on Monday, November 12th. Three analysts have rated the stock with a sell rating and three have given a hold rating to the company. The company presently has an average rating of Hold and an average price target of $43.50.
Phibro Animal Health stock opened at $32.75 on Tuesday. The company has a quick ratio of 1.82, a current ratio of 3.26 and a debt-to-equity ratio of 1.62. Phibro Animal Health has a fifty-two week low of $32.02 and a fifty-two week high of $54.62. The company has a market cap of $1.31 billion, a PE ratio of 18.82, a P/E/G ratio of 2.79 and a beta of 0.77.
The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 19th. Stockholders of record on Wednesday, November 28th will be paid a dividend of $0.12 per share. This represents a $0.48 annualized dividend and a dividend yield of 1.47%. The ex-dividend date is Tuesday, November 27th. This is an increase from Phibro Animal Health’s previous quarterly dividend of $0.10. Phibro Animal Health’s payout ratio is currently 27.59%.
In related news, insider Dean J. Warras sold 10,000 shares of Phibro Animal Health stock in a transaction that occurred on Thursday, November 1st. The shares were sold at an average price of $42.84, for a total transaction of $428,400.00. Following the transaction, the insider now directly owns 10,000 shares of the company’s stock, valued at $428,400. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 50.29% of the company’s stock.
Hedge funds have recently modified their holdings of the stock. BlueMountain Capital Management LLC increased its holdings in Phibro Animal Health by 60.4% during the second quarter. BlueMountain Capital Management LLC now owns 22,454 shares of the company’s stock valued at $1,034,000 after buying an additional 8,451 shares during the period. Alps Advisors Inc. purchased a new position in Phibro Animal Health during the second quarter valued at approximately $431,000. Janus Henderson Group PLC purchased a new position in Phibro Animal Health during the second quarter valued at approximately $222,000. First Trust Advisors LP increased its holdings in Phibro Animal Health by 20.0% during the second quarter. First Trust Advisors LP now owns 22,586 shares of the company’s stock valued at $1,040,000 after buying an additional 3,769 shares during the period. Finally, FMR LLC increased its holdings in Phibro Animal Health by 0.7% during the second quarter. FMR LLC now owns 171,107 shares of the company’s stock valued at $7,879,000 after buying an additional 1,109 shares during the period. 49.62% of the stock is currently owned by institutional investors.
Phibro Animal Health Company Profile
Phibro Animal Health Corporation operates as a diversified animal health and mineral nutrition company primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture.
Read More: What are retained earnings?
Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.